Moderna’s Dr. Stephen Hoge on AI and the Future of Healthcare
Dr. Stephen Hoge, President of Moderna, discusses how AI is accelerating drug discovery and personalized medicine, highlighting breakthrough results in melanoma treatment using individualized mRNA vaccines and the challenges of scaling personalized medicine in clinical trials.
Summary
The episode features three main segments from Inside Blackstone. First, A.J. Murphy, COO of Blackstone Private Equity Strategies, discusses deal-making in the current rate environment, noting that despite rising rates, deals are actively getting done with strong pipelines, particularly in energy and defense sectors. She emphasizes that private equity offers important diversification and long-term wealth creation compared to concentrated public markets. Second, Winfield Sickles provides macro analysis, highlighting the dichotomy between headwinds (geopolitics, inflation, government debt) and tailwinds (resilient economy, strong earnings, AI infrastructure boom). He emphasizes US advantages including energy independence and above-trend economic growth. The main segment features Dr. Stephen Hoge of Moderna discussing mRNA technology and AI's role in healthcare. Hoge explains that mRNA is nature's information system enabling the body to produce its own medicine. He details Moderna's breakthrough in personalized cancer treatment, specifically the melanoma trial results showing 50% improvement over standard immunotherapy by teaching each patient's immune system to recognize their unique cancer mutations (neoantigens). The company successfully manufactured individualized vaccines for approximately 800-1,000 patients across 42 countries within six-week timelines during the trial. Hoge addresses AI's role in healthcare, arguing it primarily accelerates productivity in drug design and manufacturing rather than fundamentally changing discovery, and emphasizing that clinical trial outcomes still require waiting for real-world results. He discusses the substantial capital requirements needed to scale personalized medicine manufacturing and notes upcoming phase three trials for rare genetic diseases like propionic acidemia. The discussion concludes with personal insights about optimism, the importance of combining STEM with humanities education, and Hoge's personal practice of intermittent fasting.
About this episode
On Inside Blackstone, host Christine Anderson sits down with Moderna President Dr. Stephen Hoge. He explains how mRNA works and how an algorithm helped Moderna design its COVID vaccine in about an hour. He also shares where AI is accelerating drug discovery and where the real-world limits remain. He walks through how Moderna makes an individualized cancer treatment for a single patient, and what investors may be overlooking in biotech. From Blackstone, the world’s largest alternative asset manager. More from Inside Blackstone: YouTube Apple Podcasts Find our guest: Dr. Stephen Hoge: https://www.linkedin.com/in/stephen-hoge-28b47210/ Moderna: https://www.linkedin.com/company/modernatx/ Follow Blackstone: Instagram @blackstone | X @blackstone | LinkedIn @blackstoneinc For Notes on the Road, follow Winfield Sickles on LinkedIn: https://www.linkedin.com/in/winfield-sickles-blackstone/ This recording is not an offer or sale of any security or investment product. Past performance does not predict future returns, and there is no assurance that any fund or investment will achieve its objectives or avoid significant losses. This recording may include forward-looking statements, which are uncertain and may differ from actual results materially. We do not undertake any duty to update these statements. For a discussion of some of the factors that could affect results, please see the Risk Factors section of our 10-K. All information discussed is as of the date of this recording, unless otherwise indicated.
Key Insights
- Messenger RNA functions as nature's software system, with cells communicating through mRNA instructions, and the same protein can theoretically be encoded by over 10 to the 80th different mRNA sequences, requiring sophisticated algorithms to select the optimal sequence.
- Moderna's melanoma vaccine trial demonstrated 50% clinical improvement over previous gold-standard immunotherapies by creating individualized medicines that teach each patient's immune system to recognize their unique cancer mutations (neoantigens).
- The company successfully manufactured approximately 800-1,000 individualized cancer vaccines across 42 countries with an average production timeline of six weeks, demonstrating that personalized medicine manufacturing can already operate at meaningful commercial scales.
- AI accelerates productivity in drug design and manufacturing but does not fundamentally overcome physical limitations—clinical trials still require measuring outcomes over years (e.g., waiting three years to know if cancer recurrence is prevented), creating a bottleneck despite rapid AI capabilities.
- Biotech capital investment has not scaled proportionally with AI investment, despite accelerating innovation pace, which will constrain the number of clinical trials that can run and drugs that can be manufactured, creating a pacing mismatch.
- Moderna joined a $750 million investment partnership with Blackstone to fund a large-scale efficacy study for a new influenza vaccine, which led to FDA approval in 2024, demonstrating successful capital deployment for pivotal trials.
- Dr. Hoge argues that optimism is a core philosophy in biotechnology and medicine because it fundamentally assumes that working hard together can make tomorrow better, even without guaranteed outcomes.
- Private equity demonstrates 30% advantages over standard-of-care flu vaccines in phase three trials with 40,000-50,000 patients globally, becoming available at retail pharmacies following FDA approval in August.
Topics
Transcript
Melanoma used to be a death sentence. What if we could teach your immune system what your cancer looks like? Instead of just getting you know, angry, if you will, and running around the body saying, are there any cancer cells here? Could we actually train it on what your cancer looks like? Hello and welcome to Inside Blackstone. I’m Christine Anderson, Global Head of Corporate Affairs, and here’s today’s lineup. First, it’s A.J. Murphy, Chief Operating Officer of Blackstone Private Equity Strategies, she joins us for the Monday Morning Meeting. Then, it’s Winfield Sickles joining me for the Economic Weather Report and his hot take on the macro. And then the main event, Dr. Stephen Hoge, President of Moderna,…
Full transcript available for MurmurCast members
Sign Up to AccessMore from Inside Blackstone
FIGS CEO Trina Spear on Scrubs, The Power of Customer Obsession, and the Jobs AI Can't Replace
FIGS CEO Trina Spear discusses building a multi-billion-dollar healthcare apparel company from an overlooked market opportunity, emphasizing customer obsession as a core strategy. The episode also covers data center regulation challenges, economic resilience driven by productivity gains, and healthcare workers' resilience to AI disruption despite industry transformation.
Ari Emanuel on the Future of Entertainment in the Age of AI
Inside Blackstone episode features Michael Chae discussing recent market volatility and strong fundamentals, followed by Ari Emanuel's perspective on AI's impact on entertainment, his new live experiences company MARI, and why live sports and events are becoming increasingly valuable. The episode concludes with Chris James explaining Blackstone's investment thesis in live entertainment as a scarce, emotionally-connective asset class.
Ramp Co-Founder and Co-CEO Eric Glyman on AI Adoption, Jobs, and Token Spend
Eric Glyman, Co-Founder and Co-CEO of Ramp, discusses how his company's access to spending data from 85,000+ businesses reveals rapid AI adoption across corporate America, productivity gains, and job growth—while also detailing Ramp's unconventional consumer-like marketing approach for a B2B fintech product.
Axios Co-Founders Jim VandeHei and Mike Allen on the 2026 Midterms, AI, and Simplifying Your Life
This Inside Blackstone episode features Axios co-founders Jim VandeHei and Mike Allen discussing the upcoming midterms, the transformative potential of AI technology, and lessons from building a successful media company, followed by expert analysis on implications for business and markets.